Celldex announces 1-for-15 reverse stock split
Celldex Therapeutics announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation. Beginning on February 11, 2019, Celldex's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the new CUSIP number 15117B202. As previously disclosed, at the Company's Annual Meeting of Stockholders held on June 13, 2018, Celldex stockholders approved a proposal authorizing the Company's Board of Directors to effect a reverse stock split by a ratio of not less than one-for-ten and not more than one-for-fifteen. The reverse stock split uniformly affects all issued and outstanding shares of the Company's common stock. The reverse stock split will not alter any stockholder's percentage ownership interest in Celldex, except to the extent that the reverse stock split results in fractional shares. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment based on the closing sales price of the Company's common stock on February 7, 2019. The par value of the Company's common stock will remain unchanged at $0.001 per share after the reverse stock split. The reverse stock split proportionately affects the number of shares of common stock available for issuance under the Company's equity incentive plans and proportionately reduces the number of shares of common stock issuable upon the exercise of stock options immediately prior to the reverse split. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 181.8 million to approximately 12.1 million. There is no change to the number of authorized shares.